Lipicard's anti-platelet drug fastest to market

Hyderabad, November 20, 2006 - Platrol® has demonstrated 40% more efficacy and negligible toxicity in limited clinical trials resulting in higher therapeutic index compared to Aspirin, Clopidogrel and other anti-platelet drugs. And Platrol®'s inherent sustained release property makes it even better as a long-term cardio-protective drug.

The most talked about antiplatelet drug currently in research pipeline is Prasugrel - ADP receptor antagonist similar to Clopidogrel. Prasugrel is being jointly developed by Daiichi Sankyo and Eli Lily. According to Eli Lily, Prasugrel in Phase I trials using healthy volunteers has shown better inhibition of platelet aggregation than Clopidogrel, but the safety profile is comparable to that of Clopidogrel. Prasugrel essentially has higher efficacy but no better toxicity profile as compared to Clopidogrel.

However, Prasugrel has to go through an intensive Phase III clinical program to translate the better platelet inhibition seen in Phase I studies to improved clinical outcomes in terms of reducing MI and other CAD instances and death compared to Clopidogrel - essentially an expensive and time consuming study similar to CAPRIE study done for establishing Clopidogrel's marginal superiority over Aspirin.

Platrol® has multiple advantages as a novel high therapeutic index antiplatelet drug and definitely scores over Prasugrel:

-- Much better safety profile - negligible GI toxicity as compared to Clopidogrel and by inference Prasugrel.

-- Faster route to market as it can get approved for other indications as well.

-- While Clopidogrel might become extinct on arrival of Prasugrel (both targeting P2Y12 receptors), Platrol® will be used for long term preventive cardio-protection as well as in tandem with Prasugrel as Platrol inhibits Thromboxane A 2 synthesis.

Prasad Sambaru, CEO Lipicard Technologies feels that Platrol is a truly safe antiplatelet drug for long term cardio-protection as well as for reducing the adverse clinical incidences after interventional cardiac surgery.

About Lipicard Technologies:

Lipicard Technologies Limited develops innovative and novel High Therapeutic Index Drugs for Lipid management and cardio protection in collaboration with Life Enhancing Technologies LLC. USA. PLATROL® is the first safe antiplatelet drug being developed for cardio-protection. Next in line are the integrated Lipid management drug for increasing HDL and lowering LDL, and safe NSAIDs.

PLATROL® is registered trademarks of Life Enhancing Technologies.